drugset / Trial / NCT05246995
A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of IBI325 combined with Sintilimab in patients with advanced solid tumors
Timeline
- Start
- 2022-03-23
- Primary completion
- 2023-03-23
- Completion
- 2023-11-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |